Bombardier Positions Challenger 3500 Business Jet Mockup in Olbia, Italy, For Customer Viewings Throughout the Summer

The Bombardier Challenger 3500 aircraft mockup
Bombardier Challenger 3500 aircraft mockup

Bombardier Positions Challenger 3500 Business Jet Mockup in Olbia, Italy, For Customer Viewings Throughout the Summer

  • The Bombardier Challenger 3500 business jet mockup is presented at the Costa Smeralda Airport in Olbia, Italy, after stops in Paris and Nice
  • Full-size mockup is on display throughout the summer at the Sardinia FBO, showcasing to clients the Challenger 3500 award-winning cabin and exclusive Nuage seat
  • Exceptional comfort, remarkable performance, and trusted reliability make the Challenger 3500 stand out as a leading choice in business aviation

OLBIA, Italy, July 08, 2024 (GLOBE NEWSWIRE) — Bombardier is excited to announce the presence of the Challenger 3500 aircraft mockup at the private terminal of the Costa Smeralda Airport in Olbia, Italy. Throughout the summer, business aviation clients will have a firsthand opportunity to experience the award-winning cabin and see the revolutionary seating of the super midsize jet. The journey of the full-size aircraft mockup included stops in Paris and Nice, France, and provides a convenient setting for European clients to discover the innovative and sophisticated features that make the Bombardier Challenger 3500 the leader in its class.

“The presence of the Bombardier Challenger 3500 mockup in a frequented travel destination such as Olbia is a testament to our commitment to providing a stress-free and easy access to product viewing,” said Emmanuel Bornand, Vice President, International Sales, Bombardier. “This is one of the many ways we make the business aviation experience unique. Every step of the way, we consistently tailor our services and support to meet our clients at their altitude, and that only comes from a genuine understanding of who they are and what they need. We are thankful to have this opportunity to showcase the amazing comfort, luxury and seamless technological features of the best-selling Challenger 3500 in the beautiful Sardinian FBO.”

The Challenger 3500 business jet, ‘’Best of the Best’’ laureate of the prestigious Red Dot Awards for Product Design, boasts the widest cabin in its class, providing passengers with an unparalleled sense of space and comfort. The custom-made cabin is a pinnacle of innovation and luxury, featuring the industry’s first integrated voice-controlled technology in its segment, 4K monitors, and Bombardier’s revolutionary Nuage seats that offer peerless comfort and support by mimicking the natural movements of the human body.

Designed with wellness in mind, the state-of-the-art aircraft has also the lowest cabin altitude in its class, standing at 4,850 feet, which significantly reduces passenger fatigue and enhances overall well-being. Advanced sound insulation contributes to a serene travel environment, allowing passengers to work, rest, or converse in peace.

The Challenger 3500 has an impressive range, capable of flying 3,400 nautical miles (6,297 kilometers), which allows the aircraft to fly out of Olbia to anywhere non-stop in Europe and in most sought-after cities of Africa and the Middle East, including Abu Dhabi, Lagos, Nairobi and Brazzaville. This remarkable range is complemented by the super midsize jet’s ability to operate in challenging airports around the world, thanks to its takeoff distance of 4,835 feet (1,474 meters) and a landing distance of 2,308 feet (703 meters).

The pilot-centric avionics suite of the Challenger 3500 ensures a seamless flight experience, and the overall aircraft performance capabilities can be trusted to offer a striking dispatch reliability rate of over 99.8%. With the lowest direct operating costs in its class, the Challenger 3500 represents reliability and value.

Guests of the Costa Smeralda Airport are welcome to visit the Bombardier Challenger 3500 mockup anytime without appointment throughout the months of July and August. Clients interested in discovering the super midsize jet can also book a private viewing by contacting the Bombardier Sales team.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of approximately 5,000 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico.

For Information

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book and Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Marie-Andrée Charron
+1-514-441-2598
marie-andree.charron@aero.bombardier.com

BombardierChallengerChallenger 3500 and Nuage are trademarks of Bombardier Inc. or its subsidiaries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f880a97-5cc5-45fa-b468-d6e99980704f

GlobeNewswire Distribution ID 9174356

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe.

HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one-time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life-changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi-year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life-threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE-B Trial

The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment-related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported.

Long-term three-year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long-lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: Stephanie.Fuchs@cslbehring.com

References


1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021-1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923-931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265-E275.

GlobeNewswire Distribution ID 1000969961

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank

Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (“OSA”), today announced that it has signed a €37.5 million loan facility agreement with the European Investment Bank (“EIB”). The agreement is backed by the European Commission’s InvestEU program. Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S.

The €37.5 million facility is divided into three tranches: €10 million for the first tranche (“Tranche A”), €13.75 million for the second tranche (“Tranche B”) and €13.75 million for the third tranche (“Tranche C”). Disbursement under the various tranches is subject to certain conditions. Tranche A carries an annual 5% cash and 5% capitalized interest rate, and features a five-year bullet repayment schedule. The various tranches do not contain revenue or liquidity covenants.

In connection with the loan facility agreement, and as a condition to drawdown thereunder, the Company also intends to enter into a “synthetic warrant agreement” with the EIB. Under the intended synthetic warrant agreement, in consideration for the facility, in connection with each tranche of the facility, the EIB will be granted “synthetic warrants” with a duration of 20 years. The number and strike price of the synthetic warrants will be calculated based on tranche specific formulas provided for in the synthetic warrant agreement. The synthetic warrants can be exercised as of the maturity date of the relevant tranche of the facility or, in exceptional situations, earlier. Such synthetic warrants will entitle the EIB to receive from the Company a cash consideration equal to the 20-day volume weighted average price of a share in the Company on the stock exchange, reduced by the applicable strike price per synthetic warrant, and multiplied by the number of synthetic warrants that the EIB exercises. In connection with Tranche A, it is expected that the EIB will be granted 468,384 synthetic warrants with a strike price of €8,11 that the EIB can exercise after the maturity of Tranche A (5 years) or, in exceptional situations, earlier.

Since certain provisions of the loan facility agreement and the synthetic warrant agreement are dependent on a change of control, those provisions will be submitted for approval to a shareholders’ meeting of the Company in accordance with article 7:151 of the Belgian Companies and Associations Code.

EIB Vice-President Robert de Groot said: “Belgium stands at the forefront of innovation in the area of life sciences and med tech. As the EIB, we take pride in supporting this thriving industry and fostering growth. Nyxoah, with its groundbreaking approach, is making a valuable contribution. We are eager to see the company progressing, benefitting patients worldwide.”

Olivier Taelman, CEO of Nyxoah, commented: “We are excited and grateful for the support and confidence in our cutting-edge technology shown by the European Investment Bank. This loan follows our recent successful equity offering where we raised €48.5 million, providing us a combined access to over €80 million in growth capital. This will aid in the commercialization of Genio in Europe and in the U.S., if approved, while helping increase production capacity and sustain innovation.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please see the Company’s annual report for the financial year 2023 and visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the entry into of the loan facility agreement and the synthetic warrant agreement with the EIB; the use of proceeds from the loan facility agreement; the Genio® system and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu

Attachment

GlobeNewswire Distribution ID 1000969769

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

  • Apparel Group hosted a lifestyle shoot in partnership with Anantara The Palm Resort, showcasing their summer collections that are available in store and on 6thstreet.com.
  • Celebrating Summer Time with Apparel Group Brands – Aldo, Aldo Accessories, Ardene, Asics, Athlete’s Co., Beverly Hills Polo Club, Birkenstock, Calvin Klein, Charles & Keith, Cold Stone Creamery, Crocs, Dune London, F5 Global, Forest Essentials, Forever New, Havaianas, Herschel, Inglot, Jamie’s Italian, La Vie En Rose, LC Waikiki, LCW Home, New Yorker, Nine West, Not Ordinary, Nysaa, R&B Kids, Rituals, Skechers, Steve Madden, The Children’s Place, Tim Hortons and Tommy Hilfiger

DUBAI, United Arab Emirates, July 03, 2024 (GLOBE NEWSWIRE) — Apparel Group, a leading retail and lifestyle conglomerate, is excited to announce the release of their newest Summer Time campaign showcasing summer collections from more than 36 Apparel Group brands. In collaboration with Anantara The Palm Resort, this lifestyle shoot combines the fashion-forward expertise of Apparel Group with the luxurious ambiance and pristine settings, promising a summer collection that redefines style and elegance.

Mrs. Sima Ganwani Ved, Founder and Chairwoman of Apparel Group, expressed her enthusiasm for the launch, stating, “We are so excited to share Apparel Group’s summer look-book for 2024, with over 36 of Apparel Group international and home grown brands, each bringing their unique flair to this exciting season. This summer campaign is not just about showcasing our summer collection but creating a lifestyle experience that resonates with our customers.”

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

The summer campaign features a stellar lineup of Apparel Group’s celebrated international and home grown brands, including Aldo, Aldo Accessories, Ardene, Asics, Athlete’s Co., Beverly Hills Polo Club, Birkenstock, Calvin Klein, Charles & Keith, Cold Stone Creamery, Crocs, Dune London, F5 Global, Forest Essentials, Forever New, Havaianas, Herschel, Inglot, Jamie’s Italian, La Vie En Rose, LC Waikiki, LCW Home, New Yorker, Nine West, Not Ordinary, Nysaa, R&B Kids, Rituals, Skechers, Steve Madden, The Children’s Place, Tim Hortons and Tommy Hilfiger. Each brand will bring its unique style and flair, offering everything from casual chic to summer glamour. The collection promises to cater to a wide range of style preferences, ensuring there is something special for everyone.

Customers eager to embrace the summer vibes can look forward to shopping the collection on Apparel Group store outlets and e-commerce platform, 6thStreet.com, where the full range of products will be available. Blending retail innovation with luxury hospitality, this campaign highlights the synergy between Apparel Group and Anantara The Palm Resort catering to residents and tourists positioning the region as the ultimate summer destination.

Stay tuned for a summer of style, sophistication, and scenic beauty, exclusively brought to you by Apparel Group and Anantara The Palm Resort.

ABOUT APPAREL GROUP LLC

Apparel Group is a global fashion and lifestyle retail conglomerate residing at the crossroads of the modern economy – Dubai, United Arab Emirates. Today, Apparel Group caters to thousands of eager shoppers through its 2200+ retail stores and 85+ brands on all platforms while employing over 22,000+ multicultural staff.

Apparel Group has carved its strong presence in the GCC and expanded thriving gateways to market in India, South Africa, Singapore, Indonesia, Thailand, Malaysia, and Egypt. Additionally, clear strategies are in place to enter emerging markets such as Hungary and Philippines.

Apparel Group has created an omni-channel experience, operating brands originating from the USA, Canada, Europe, Australia, and Asia. The brands include leading names in fashion, footwear, and lifestyles such as Tommy Hilfiger, Charles & Keith, Skechers, Aldo, Nine West, Aeropostale, Jamie’s Italian, Tim Hortons, Cold Stone Creamery, Inglot, and Rituals.

Apparel Group owes its amazing growth to the vision and guidance of its dynamic Founder and Chairwoman, Mrs. Sima Ganwani Ved, who has taken the company from strength to strength since its inception in the last two decades.

https://apparelglobal.com/en/
PR@apparelglobal.com

About Anantara The Palm Resort

Anantara is a luxury hospitality brand for modern travellers, connecting them to genuine places, people and stories through personal experiences, and providing heartfelt hospitality in the world’s most exciting destinations. The collection of distinct, thoughtfully designed luxury hotels and resorts provides a window through which to journey into invigorating new territory, curating personal travel experiences.

From cosmopolitan cities to desert sands to lush islands, Anantara connects travellers to the indigenous, grounds them in authentic luxury, and hosts them with passionate expertise. The portfolio currently boasts over 40 stunning hotels and resorts located in Thailand, Maldives, Indonesia, Vietnam, China, Cambodia, Malaysia, Sri Lanka, Mauritius, Seychelles, Mozambique, Zambia, UAE, Qatar, Oman, Tunisia, Portugal, Spain, Hungary, The Netherlands, Italy, Ireland and France, with a pipeline of future properties across Asia, the Middle East, Europe and South America.

For more information on Anantara Hotels, Resorts & Spas, please visit www.anantara.com

Follow us on Facebook: www.facebook.com/anantara; Twitter and Instagram: @anantara_hotels

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/3c050648-49b9-4720-bd36-03eee8be5739

https://www.globenewswire.com/NewsRoom/AttachmentNg/30b0f74f-7194-40d2-9530-8abe169e79c0

GlobeNewswire Distribution ID 9172820

DigiAsia Corp. Announces Completion of Convertible Note Financing with Helena Partners and Extinguishes Outstanding Debt

~ Prompt Extinguishment of Debt Following Recent Listing as a Public Company Prioritizes Financial Responsibility with a Healthy Capital Structure ~

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced it has received net proceeds of $3.0 million as a result of the previously announced Securities Purchase Agreement (“SPA”) with Helena Special Opportunities LLC, an affiliate of Helena Partners Inc. (“Helena”). In addition, through the issuance of Senior Unsecured Convertible Notes (the “Notes”), convertible into Class A common shares of the Company, and $5.2 million of Class B Convertible Notes, DigiAsia has extinguished all debt inherited from its business combination with StoneBridge Acquisition Corporation. The remainder of proceeds will be utilized for general corporate purposes as growth capital investment.

As announced on June 21, 2024, the Notes bear interest at a rate of 12% per annum, payable quarterly, and mature one year from the issuance of the note. Helena, pursuant to its note, has the option, on or prior to the maturity date, to convert the entire principal amount and all accrued but unpaid interest on the notes into shares of DigiAsia common stock.

EF Hutton LLC acted as the exclusive placement agent for the offering. Winston & Strawn LLP acted as legal advisor to DigiAsia.

Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20-F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward-looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:

Subir Lohani

Chief Financial Officer and Chief Strategy Officer

646-480-0142

Investor Contact:

MZ North America

Email: FAAS@mzgroup.us

GlobeNewswire Distribution ID 9172144

DigiAsia Corp. Announces Completion of Convertible Note Financing with Helena Partners and Extinguishes Outstanding Debt

~ Prompt Extinguishment of Debt Following Recent Listing as a Public Company Prioritizes Financial Responsibility with a Healthy Capital Structure ~

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced it has received net proceeds of $3.0 million as a result of the previously announced Securities Purchase Agreement (“SPA”) with Helena Special Opportunities LLC, an affiliate of Helena Partners Inc. (“Helena”). In addition, through the issuance of Senior Unsecured Convertible Notes (the “Notes”), convertible into Class A common shares of the Company, and $5.2 million of Class B Convertible Notes, DigiAsia has extinguished all debt inherited from its business combination with StoneBridge Acquisition Corporation. The remainder of proceeds will be utilized for general corporate purposes as growth capital investment.

As announced on June 21, 2024, the Notes bear interest at a rate of 12% per annum, payable quarterly, and mature one year from the issuance of the note. Helena, pursuant to its note, has the option, on or prior to the maturity date, to convert the entire principal amount and all accrued but unpaid interest on the notes into shares of DigiAsia common stock.

EF Hutton LLC acted as the exclusive placement agent for the offering. Winston & Strawn LLP acted as legal advisor to DigiAsia.

Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20-F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward-looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:

Subir Lohani

Chief Financial Officer and Chief Strategy Officer

646-480-0142

Investor Contact:

MZ North America

Email: FAAS@mzgroup.us

GlobeNewswire Distribution ID 9172144

Call for Nominations: 2024 Global Citizen Award

LONDON, July 02, 2024 (GLOBE NEWSWIRE) — Leading international residence and citizenship advisory firm Henley & Partners, in partnership with Andan Foundation, a Swiss non-profit humanitarian organization, is pleased to announce the call for nominations for the 2024 Global Citizen Award.

Created ten years ago in 2014, the Global Citizen Award is a tribute that honors remarkable individuals working to advance any one of the global challenges affecting humanity today – challenges that transcend national boundaries and cannot be resolved by any one country acting alone. This year’s honor is particularly significant as it marks the 10th anniversary of the Global Citizen Award, celebrating a decade of recognizing and supporting global champions who make a profound impact on our world.

The 2024 laureate will be selected by a distinguished, independent committee and honored at the Global Citizen Award ceremony, the concluding gala evening event of the annual Henley & Partners Global Citizenship Conference which is taking place this year at Capella Singapore from 27–29 November 2024.

Henley & Partners Chairman and Founder of the Andan Foundation, Dr. Christian H. Kaelin, says the awardee’s work needs to demonstrate a positive impact on the lives of vulnerable social groups, particularly with a connection to migration-related issues. “The Global Citizen Award is open worldwide to those working in a field with a direct link to the issues they are looking to affect and excludes political figures, opinion leaders, and celebrities. The committee is looking for remarkable and inspirational individuals who demonstrate vision, courage, and innovation in driving global change, and whose actions and outlook contribute to a more just, peaceful, connected, and tolerant world.”

The selection process is confidential and is based on a majority decision of the Award Committee. The award itself consists of a bespoke sculptural medal designed by leading Italian artist Antonio Nocera, an award certificate signed by the Chairman of the Global Citizen Award Committee, and a monetary prize of USD 20,000, which goes towards supporting the awardee’s humanitarian efforts. In addition, Henley & Partners commits to working closely with the awardee for a period of one year, raising awareness of their work and supporting the selected project through the firm’s network of more than 55 offices worldwide.

Since its inception, the Global Citizen Award has honored many remarkable individuals. The first laureate was German entrepreneur Harald Höppner, who set up the refugee humanitarian aid project Sea-Watch. He was followed by Dr. Imtiaz Sooliman, Founder of the Gift of the Givers Foundation, Africa’s largest disaster relief organization, and Monique Morrow, Co-Founder of The Humanized Internet, a digital identity project that aims to bring hope to the estimated 1.1 billion individuals in the world who cannot prove their legal identity.

Diep Vuong, Co-Founder and President of the Pacific Links Foundation, was awarded for her work in Southeast Asia campaigning for the rights of those enslaved by human trafficking, while Prof. Dr. Padraig O’Malley received his Global Citizen Award in recognition of his work on conflict resolution and reconciliation in Northern Ireland, South Africa, and Iraq. Last year’s awardee Zannah Bukar Mustapha, the Founder of the Future Prowess Islamic Foundation, was recognized for the psychological, educational, spiritual and other developmental support provided to the children and widows affected by the insurgency in north-eastern Nigeria.

Commenting on the award’s 10-year history and significance, Dr. Kaelin says global citizenship ideals are a founding principle of Henley & Partners, and through its partnership with the Andan Foundation, the firm can provide support to those displaced by war, conflict and climate change. “All of our Global Citizen Award laureates have inspired us with their willingness to act in confronting a problem that many see as simply too vast to address. The issues that we face today transcend the family, the tribe, the village, and the nation. It’s more critical than ever that we do what we can to support those working to change the lives of vulnerable people around the world.”

Nominations close on Friday, 2 August 2024. For more information on how to submit your nomination, please contact Bushra Zaidan at  bushra.zaidan@andan.org

Sarah Nicklin
Group Head of PR
sarah.nicklin@henleyglobal.com
Mobile: +27 72 464 8965

GlobeNewswire Distribution ID 1000969321

Call for Nominations: 2024 Global Citizen Award

LONDON, July 02, 2024 (GLOBE NEWSWIRE) — Leading international residence and citizenship advisory firm Henley & Partners, in partnership with Andan Foundation, a Swiss non-profit humanitarian organization, is pleased to announce the call for nominations for the 2024 Global Citizen Award.

Created ten years ago in 2014, the Global Citizen Award is a tribute that honors remarkable individuals working to advance any one of the global challenges affecting humanity today – challenges that transcend national boundaries and cannot be resolved by any one country acting alone. This year’s honor is particularly significant as it marks the 10th anniversary of the Global Citizen Award, celebrating a decade of recognizing and supporting global champions who make a profound impact on our world.

The 2024 laureate will be selected by a distinguished, independent committee and honored at the Global Citizen Award ceremony, the concluding gala evening event of the annual Henley & Partners Global Citizenship Conference which is taking place this year at Capella Singapore from 27–29 November 2024.

Henley & Partners Chairman and Founder of the Andan Foundation, Dr. Christian H. Kaelin, says the awardee’s work needs to demonstrate a positive impact on the lives of vulnerable social groups, particularly with a connection to migration-related issues. “The Global Citizen Award is open worldwide to those working in a field with a direct link to the issues they are looking to affect and excludes political figures, opinion leaders, and celebrities. The committee is looking for remarkable and inspirational individuals who demonstrate vision, courage, and innovation in driving global change, and whose actions and outlook contribute to a more just, peaceful, connected, and tolerant world.”

The selection process is confidential and is based on a majority decision of the Award Committee. The award itself consists of a bespoke sculptural medal designed by leading Italian artist Antonio Nocera, an award certificate signed by the Chairman of the Global Citizen Award Committee, and a monetary prize of USD 20,000, which goes towards supporting the awardee’s humanitarian efforts. In addition, Henley & Partners commits to working closely with the awardee for a period of one year, raising awareness of their work and supporting the selected project through the firm’s network of more than 55 offices worldwide.

Since its inception, the Global Citizen Award has honored many remarkable individuals. The first laureate was German entrepreneur Harald Höppner, who set up the refugee humanitarian aid project Sea-Watch. He was followed by Dr. Imtiaz Sooliman, Founder of the Gift of the Givers Foundation, Africa’s largest disaster relief organization, and Monique Morrow, Co-Founder of The Humanized Internet, a digital identity project that aims to bring hope to the estimated 1.1 billion individuals in the world who cannot prove their legal identity.

Diep Vuong, Co-Founder and President of the Pacific Links Foundation, was awarded for her work in Southeast Asia campaigning for the rights of those enslaved by human trafficking, while Prof. Dr. Padraig O’Malley received his Global Citizen Award in recognition of his work on conflict resolution and reconciliation in Northern Ireland, South Africa, and Iraq. Last year’s awardee Zannah Bukar Mustapha, the Founder of the Future Prowess Islamic Foundation, was recognized for the psychological, educational, spiritual and other developmental support provided to the children and widows affected by the insurgency in north-eastern Nigeria.

Commenting on the award’s 10-year history and significance, Dr. Kaelin says global citizenship ideals are a founding principle of Henley & Partners, and through its partnership with the Andan Foundation, the firm can provide support to those displaced by war, conflict and climate change. “All of our Global Citizen Award laureates have inspired us with their willingness to act in confronting a problem that many see as simply too vast to address. The issues that we face today transcend the family, the tribe, the village, and the nation. It’s more critical than ever that we do what we can to support those working to change the lives of vulnerable people around the world.”

Nominations close on Friday, 2 August 2024. For more information on how to submit your nomination, please contact Bushra Zaidan at  bushra.zaidan@andan.org

Sarah Nicklin
Group Head of PR
sarah.nicklin@henleyglobal.com
Mobile: +27 72 464 8965

GlobeNewswire Distribution ID 1000969321

Call for Nominations: 2024 Global Citizen Award

LONDON, July 02, 2024 (GLOBE NEWSWIRE) — Leading international residence and citizenship advisory firm Henley & Partners, in partnership with Andan Foundation, a Swiss non-profit humanitarian organization, is pleased to announce the call for nominations for the 2024 Global Citizen Award.

Created ten years ago in 2014, the Global Citizen Award is a tribute that honors remarkable individuals working to advance any one of the global challenges affecting humanity today – challenges that transcend national boundaries and cannot be resolved by any one country acting alone. This year’s honor is particularly significant as it marks the 10th anniversary of the Global Citizen Award, celebrating a decade of recognizing and supporting global champions who make a profound impact on our world.

The 2024 laureate will be selected by a distinguished, independent committee and honored at the Global Citizen Award ceremony, the concluding gala evening event of the annual Henley & Partners Global Citizenship Conference which is taking place this year at Capella Singapore from 27–29 November 2024.

Henley & Partners Chairman and Founder of the Andan Foundation, Dr. Christian H. Kaelin, says the awardee’s work needs to demonstrate a positive impact on the lives of vulnerable social groups, particularly with a connection to migration-related issues. “The Global Citizen Award is open worldwide to those working in a field with a direct link to the issues they are looking to affect and excludes political figures, opinion leaders, and celebrities. The committee is looking for remarkable and inspirational individuals who demonstrate vision, courage, and innovation in driving global change, and whose actions and outlook contribute to a more just, peaceful, connected, and tolerant world.”

The selection process is confidential and is based on a majority decision of the Award Committee. The award itself consists of a bespoke sculptural medal designed by leading Italian artist Antonio Nocera, an award certificate signed by the Chairman of the Global Citizen Award Committee, and a monetary prize of USD 20,000, which goes towards supporting the awardee’s humanitarian efforts. In addition, Henley & Partners commits to working closely with the awardee for a period of one year, raising awareness of their work and supporting the selected project through the firm’s network of more than 55 offices worldwide.

Since its inception, the Global Citizen Award has honored many remarkable individuals. The first laureate was German entrepreneur Harald Höppner, who set up the refugee humanitarian aid project Sea-Watch. He was followed by Dr. Imtiaz Sooliman, Founder of the Gift of the Givers Foundation, Africa’s largest disaster relief organization, and Monique Morrow, Co-Founder of The Humanized Internet, a digital identity project that aims to bring hope to the estimated 1.1 billion individuals in the world who cannot prove their legal identity.

Diep Vuong, Co-Founder and President of the Pacific Links Foundation, was awarded for her work in Southeast Asia campaigning for the rights of those enslaved by human trafficking, while Prof. Dr. Padraig O’Malley received his Global Citizen Award in recognition of his work on conflict resolution and reconciliation in Northern Ireland, South Africa, and Iraq. Last year’s awardee Zannah Bukar Mustapha, the Founder of the Future Prowess Islamic Foundation, was recognized for the psychological, educational, spiritual and other developmental support provided to the children and widows affected by the insurgency in north-eastern Nigeria.

Commenting on the award’s 10-year history and significance, Dr. Kaelin says global citizenship ideals are a founding principle of Henley & Partners, and through its partnership with the Andan Foundation, the firm can provide support to those displaced by war, conflict and climate change. “All of our Global Citizen Award laureates have inspired us with their willingness to act in confronting a problem that many see as simply too vast to address. The issues that we face today transcend the family, the tribe, the village, and the nation. It’s more critical than ever that we do what we can to support those working to change the lives of vulnerable people around the world.”

Nominations close on Friday, 2 August 2024. For more information on how to submit your nomination, please contact Bushra Zaidan at  bushra.zaidan@andan.org

Sarah Nicklin
Group Head of PR
sarah.nicklin@henleyglobal.com
Mobile: +27 72 464 8965

GlobeNewswire Distribution ID 1000969321

Adrian Ridge Appointed CEO of Nikkiso Clean Energy & Industrial Gases Group

Adrian Ridge
Adrian Ridge CEO Nikkiso Clean Energy & Industrial Gases

Effective July 1, 2024, Adrian Ridge is CEO of Nikkiso Clean Energy & Industrial Gases

TEMECULA, Calif., July 01, 2024 (GLOBE NEWSWIRE) — Effective July 1, 2024, Adrian Ridge is Chief Executive Officer of Nikkiso Clean Energy & Industrial Gases Group, part of Nikkiso Co. Ltd.’s Industrial division. Ridge succeeds Peter Wagner, who remains engaged in a Board role as Executive Chairman for Nikkiso CE&IG Group.

As CEO, Ridge will drive operational and financial results and ready the Group for future growth. In his role as Executive Chairman, Wagner will focus on driving the vision and long-term strategy of the Group in an advisor capacity.

“On behalf of the Board, I welcome and congratulate Adrian on his promotion to CEO,” said Wagner. “He is a proven leader who is engaging at the right time to support Nikkiso Clean Energy & Industrial Gases’s growth to new heights.”

“I’ve never been as excited about a company’s potential as I am about Nikkiso,” said Ridge. “We have all the right ingredients to be a leader in every market we serve in every region around the world. I am honored and grateful for this once-in-a-lifetime opportunity.”

About Adrian Ridge

Ridge joined Nikkiso Clean Energy & Industrial Gases in 2022 as EVP of Manufacturing and Operations after working approximately 30 years at Swedish manufacturing giant Atlas Copco in various global leadership roles. He has a Mechanical Engineering degree and an MBA from Durham University in the United Kingdom.

Media contact
Lisa Adams
Lisa.adams@nikkisoceig.com
Mobile: +1 (405) 492-1689

About Nikkiso Clean Energy & Industrial Gases Group

The Nikkiso Clean Energy & Industrial Gases Group is a leading provider of cryogenic equipment, technologies and applications for clean energy and industrial gas market segments. The Group employs more than 1,600 people in 22 countries and is headed by Cryogenic Industries, Inc. in Southern California, U.S., which is a wholly owned subsidiary of Nikkiso Co., Ltd. (TSE: 6376).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3496ba9-85d1-4c91-b199-181d30747a25

GlobeNewswire Distribution ID 9171987

In Rapid Rise of AI, Employers Turn to Business School Graduates for Human Skills

GMAC’s annual survey of corporate recruiters indicates high confidence, predicts strong hiring

RESTON, Va., July 01, 2024 (GLOBE NEWSWIRE) —  Despite concerns about inflation and recession risk, employer confidence in graduate management education (GME) and its ability to prepare business school graduates to be successful in their organizations has reached new heights since the pandemic, according to an annual survey of global corporate recruiters of business graduates released today by the Graduate Management Admission Council (GMAC). This increase in confidence was seen across key industries business education caters to like consulting, finance and accounting, as well as technology. The best news for today’s business school graduates is that employers’ appreciation translates into optimistic hiring projections, with the majority of global recruiters planning steady or expanding hiring in 2024. A third expected to hire more MBA graduates than last year.

Notably, employers’ renewed confidence in GME is reflected in the growing number of them who say business school graduates tend to outperform their other employees, fast-track to upper-level positions, and earn more than other employees, and the share has grown in recent years despite – or perhaps due to – the rapid rise of technologies like generative artificial intelligence (AI). With the attention AI has received, the responding employers do not necessarily believe the predicted changes have hit their workplaces just yet, with only 26 percent considering AI to be an important skill for current GME graduates to leverage in their organizations. However, when asked which skills will be most important in five years, AI ranked high across regions and industries. More importantly, employers consistently value problem-solving and strategic thinking as the top skills for GME graduates of both today and tomorrow, and these core competencies are seen as essential around the globe.

“As disruptive technologies like generative AI reshape the labor market and the skill economy expands, employers are putting a premium on strategic thinking, people leadership, and problem-solving while betting on the rising importance of tech prowess. To achieve success, future business leaders will need to harness technological advancements and possess the knowledge and experience to manage the change brought on by these evolutions,” said Joy Jones, CEO of GMAC. “This year’s Corporate Recruiters Survey affirms that graduate business programs continue to be uniquely positioned—and trusted for their ability—to develop business talent with increasingly relevant and cutting-edge skills, who are equipped to tackle new and perennial challenges with a balance of tech and human understanding.”

Confidence growth in remote working management skills does not extend to remote learning.

Employers may have grown more confident in business schools related to the changing context in which businesses and business education operate. Notably, about two-thirds of employers say the skills gained through GME are more important in today’s world of remote and hybrid working. This is almost double the share who answered a similar question in 2021 at the peak of the pandemic. The increase in valuation of GME is most pronounced in leading Fortune 100 and 500 companies, the finance and accounting and manufacturing industries, and in East and Southeast Asia and Western Europe. Understandably, organizations in these companies, industries and regions have likely undergone the most changes in remote working situations in the years following the pandemic and are more likely to rely on the skills of GME graduates to manage this disruption.

However, employers’ new appreciation for business graduates’ ability to manage flexibility in the workplace has not entirely extended to an appreciation for the skills gained in online programs. Overall, two-thirds of employers still believe in-person programs impart stronger technical skills than online programs, and nearly three quarters of global employers agree in-person programs impart stronger leadership and communication skills. But this year U.S. employers, who in past surveys have been the most skeptical of online degrees compared to other regions, are warming up to the idea that in-person degrees do not necessarily have a leg up on online programs when it comes to development of the above-mentioned skills.

Hiring projections remain optimistic despite recession fears and policy impacts.

Given the lingering uncertainty of the global economic outlook, more than half of employers—regardless of industry or region—reported major or moderate influence of inflation and recession on hiring but remain optimistic about employment opportunities for business graduates. Consulting, along with finance and accounting sectors, are projected to hire more MBA graduates while data and business analytics hiring are expected to expand the most in 2024. Regionally, planned hiring expansion is most conservative in the United States and the technology sector, whereas employers in Asia report the highest intended hiring across GME degree types. Employers in major markets in Asia, as well as Western Europe, also demonstrated significant growth in international hiring—employment of those who require additional legal documentation—compared to pre-pandemic levels in 2018.

“We know that international education, and subsequent international employment opportunities, brings tremendous economic and social benefits to a campus and a country,” said Martin Boehm, rector & professor of marketing at EBS Universitӓt für Wirtschaft und Recht in Germany and a board member of GMAC. “It is encouraging to see the positive impact of international student recruitment by increasing diversity and enrollment from abroad. We remain committed to growing our graduates of cross-cultural competencies and their global employability.”

About the Corporate Recruiters Survey

For more than two decades, the Corporate Recruiters Survey has provided the world’s graduate business schools and employers with data and insights to understand current trends in skill demand, hiring, compensation, and perceptions of MBA and business master’s graduates. GMAC, together with survey partners European Foundation for Management Development (EFMD) and the MBA Career Services and Employer Alliance (MBA CSEA), conducted the survey from January to March of 2024, in association with the career services offices at participating graduate business schools worldwide. GMAC Research also worked with a market research firm to recruit additional participants to make the overall sample more globally representative. In total, 931 corporate recruiters and hiring managers from staffing firms in 38 countries around the world participated in this year’s survey.

About GMAC

The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry as well as resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

More than 12 million prospective students a year trust GMAC’s platforms, including mba.comGMAC Tours, and BusinessBecause, to learn about MBA and business master’s programs, connect with schools around the world, prepare and register for exams, and get advice on how to successfully achieve their business education and career goals. GMAC is a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
Mobile: 202-390-4180
thsu@gmac.com 

GlobeNewswire Distribution ID 9171500

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical products

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced the appointment of Orlando Oliveira as its Chief Commercial Officer. With a career spanning nearly 25 years, Mr. Oliveira brings a wealth of experience building high-performing global commercial teams, driving revenue growth, and fostering strategic partnerships in the biotechnology and pharmaceutical industry.

“As we continue to advance multiple mid- to late-stage clinical development programs, we are thrilled to welcome Orlando to the Zenas leadership team,” said Joe Farmer, President and Chief Operating Officer. “His expertise and track record of building and leading high performing commercial teams will be instrumental in the establishment of the obexelimab franchise and achievement of our goal to bring obexelimab to patients worldwide. We will benefit immensely from Orlando’s broad commercial knowledge and leadership as Zenas evolves to become an integrated development and commercial biopharmaceutical company.”

“I am eager to join the seasoned executive team Zenas has built, guided by their mission to deliver transformative immunology-based therapies to patients in need,” said Mr. Oliveira. “I look forward to working with this team to further develop and execute the strategies and plans for the eventual commercialization of obexelimab and to establish Zenas as a leading global immunology-based development and commercial company.”

Prior to joining Zenas, Mr. Oliveira served as Senior Vice President & Head of International at Mirati Therapeutics (acquired by Bristol Meyers Squibb), where he helped lead and set up the international foundations of the company and prepared multiple oncology launches, including leading the European Medicines Agency approval of KRAZATI®. Previously, he served as Senior Vice President & General Manager International at Agios Pharmaceuticals (oncology business acquired by Servier), and in the same capacity at TESARO (acquired by GlaxoSmithKline). Previously, he served as Vice President Europe & Intercontinental Operations at Cubist Pharmaceuticals (acquired by Merck). Mr. Oliveira also held, during more than a decade, numerous roles of increasing responsibility at Amgen. Mr. Oliveira currently serves as a Board member at OncoInvent AS, a privately held clinical-stage radiopharmaceutical company. He obtained a degree in Pharmacy and a post-graduate degree in Drug and Pharmacy Law from the University of Coimbra, Portugal.

About Zenas BioPharma

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients in need. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com

GlobeNewswire Distribution ID 9171428